The rise in precision medicine, fueled by next-generation sequencing tests and increasingly by liquid biopsy as well, has given rise to treatments targeted not to cancer types (i.e. breast, prostate, lung, etc.), but to oncogenic driver mutations. Mutations that are unique to each individual. Treating patients based on a ‘one-size fits all’ strategy doesn’t take into consideration the uniqueness of each patient. Uniqueness that new technology and science can sift out and become illuminatingly informative for advanced cancer patients. READ this article and learn about what Bryce Olson did to move away from ‘average’ based care, making a shift into a precision medicine approach. Also learn two examples of how new drugs are getting FDA approved based on a deeper understanding of the genetic abnormalities that fuel a patient’s cancer.